MAP4343
Phase 2Small molecule
MAP4343 is one of 7 small molecule programs targeting Major Depressive Episode. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Major Depressive Episode
#DrugCompanyPhaseTrials
1Ketalar
AAultman Health Foundation
Approved
Vimpat
UCBPhase 3
Suboxone
IIndivior Inc.
Phase 3
Lithobid
SSolvay Pharmaceuticals
Preclinical
MAP4343
TThe Scripps Research Institute
Phase 2
Selective Serotonin Reuptake Inhibitor
Johnson & JohnsonPreclinical
L-Methylfolate
MMassachusetts General Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MAP4343. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TThe Scripps Research Institute